IDRSF News and Press, Idorsia AG From 07/26/22

Idorsia press release ( OTCPK:IDRSF ): Q2 GAAP EPS of -CHF1.25. Revenue of CHF17M (+142.9% Y/Y). CFO comment: “Idorsia has reached another important milestone by recording its first product sales with the launches of PIVLAZ in Japan and QUVIVIQ in the US. ...

The second quarter results will be reported on Tuesday, July 26th, and will reflect the first revenue stream for two newly approved drugs. I will share with the reader what we should look for as it relates to future growth and remaining within the restraints of a proper spending budge...